Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A partial agonist approved for major depressive disorder (MDD) treatment in adults. This was 10-week, multicenter, double-blind, placebo-controlled active-controlled, fixed-dose trial (NCT01473381). Adult patients with MDD (Diagnostic Statistical Manual of Mental Disorders, 4th ed., text revision criteria) were randomized 1 : to vilazodone 20 or 40 mg/day, citalopram placebo. Primary efficacy: Montgomery-Åsberg Depression Rating...

The authors determined the efficacy and safety of asenapine in preventing recurrence any mood episode adults with bipolar I disorder.Adults an acute manic or mixed per DSM-IV-TR criteria were enrolled this randomized, placebo-controlled trial consisting initial 12- to 16-week open-label period a 26-week double-blind randomized withdrawal period. target dosage was 10 mg b.i.d. but could be titrated down 5 After completing period, subjects meeting stabilization/stable-responder placebo...

Article AbstractIntroduction: Vilazodone is a potent serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist approved by the US Food Drug Administration for treatment of major depressive disorder (MDD) in adults. This study evaluated efficacy tolerability vilazodone MDD.Method: 8-week, randomized (1:1), double-blind, placebo-controlled, parallel-group, fixed-dose conducted from January 2012 to February 2013 compared 40 mg/d with placebo outpatients DSM-IV-TR-diagnosed MDD....

ObjectiveTo evaluate asenapine versus placebo in 403 patients aged 10 to 17 years with bipolar I disorder currently manic or mixed episodes.MethodIn this double-blind, placebo-controlled, international trial, were randomized 1:1:1:1 placebo, 2.5, 5, mg b.i.d. (twice daily). Primary efficacy measure was change from baseline Young-Mania Rating Scale (YMRS) total score at day 21. Analyses of with/without attention-deficit/hyperactivity (ADHD) and stimulant use performed.ResultsThe mean...

Understanding patients' preferences for long-acting injectable (LAI) or oral antipsychotics (pills) could help reduce potential barriers to LAI use in schizophrenia.Post hoc analyses were conducted from a double-blind, randomized, non-inferiority study (NCT01515423) of 3-monthly vs 1-monthly paliperidone palmitate patients with schizophrenia. Data the Medication Preference Questionnaire, administered on day 1 (baseline; open-label stabilization phase), analyzed. The questionnaire includes...

Abstract Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disorder with variable clinical presentation. We intend to describe the clinical, biochemical, and radio-pathological profiles of PHPT patients managed over 13 years from South India. Methods: analysed all who underwent evaluation surgery for July 2011 April 2024. Results: A total 862 parathyroidectomy, female preponderance (61.2%). Analysis was done on 804 (>20 age) excluding adolescent paediatric age groups....

The purpose of this study was to evaluate the safety and efficacy asenapine in adolescents with schizophrenia.In an 8 week, randomized, double-blind placebo-controlled trial, subjects (12-17 years age) meeting Diagnostic Statistical Manual Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) criteria for schizophrenia were randomized 1:1:1 placebo, 2.5 mg b.i.d., or 5 b.i.d. Subjects who completed week acute could participate a 26 flexible-dose asenapine-only open-label extension (OLE).A...

Background Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist, is approved for treating major depressive disorder in adults. This study (NCT01629966 ClinicalTrials.gov) evaluated the efficacy safety of vilazodone adults with generalized anxiety (GAD). Methods A multicenter, double-blind, parallel-group, placebo-controlled, fixed-dose patients GAD randomized (1:1:1) to placebo (n = 223), or 20 mg/day 230) 40 227). Primary secondary parameters were total...

The pooled analysis of two double-blind, randomized, multicenter, phase-3 studies evaluated predictors improvement or worsening schizophrenia-related caregiver burden following paliperidone palmitate long-acting injectables (1-monthly [PP1M] and 3-monthly [PP3M]) treatment. Caregivers were offered to complete the involvement evaluation questionnaire (involvement questionnaire; 31-item scale). Total, 1498 caregivers (intent-to-treat open-label set, n = 1497; mean [SD] age: 51.5 [13.02] years,...

Background: This post-hoc analysis evaluated the agreement between Clinical Global Impressions-Severity (CGI-S) score- and Montgomery–Åsberg Depression Rating Scale (MADRS) total score-based assessment of response in patients with treatment-resistant depression (TRD) treated esketamine nasal spray plus a newly initiated oral antidepressant (ESK-NS + AD). Methods: Data were analyzed from phase 3, randomized, double-blind study (TRANSFORM-2) flexibly dosed or placebo oral-AD adults...

Esketamine (ESK) nasal spray, taken with oral antidepressant therapy, is approved for the treatment of depressive symptoms in adults major disorder (MDD) acute suicidal ideation or behavior. In pooled analyses two pivotal phase 3 studies, ASPIRE I and II, remission rates were consistently higher among patients MDD active suicidality who treated ESK + standard care (SOC) versus placebo (PBO) SOC at all time points double-blind most follow-up phases. The current analysis data sets assessed...

Sexual dysfunction commonly occurs with major depressive disorder (MDD). Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist antidepressant approved for the treatment of MDD in adults, was evaluated to determine its effects on sexual function. The primary study double-blind, randomized, controlled trial comparing vilazodone 20 40 mg/day placebo; citalopram an active control (NCT01473381; http://www.clinicaltrials.gov). Post-hoc analyses change from...

Objective Evaluate the efficacy and safety of asenapine 2.5 mg twice daily (bid; n=97) or 5 bid (n=113) versus placebo (n=101) in adults with acute exacerbation schizophrenia. Methods Adults Diagnostic Statistical Manual Mental Disorders , Fourth Edition, Text Revision (DSM-IV-TR) schizophrenia diagnosis were randomized to bid, placebo, olanzapine 15 once daily. The primary objective was test superiority as measured by change from baseline day 42 Positive Negative Syndrome Scale (PANSS)...

Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist that approved for treatment of major depressive disorder in adults the USA Mexico. The efficacy, safety, tolerability vilazodone generalized anxiety (GAD) were investigated clinical trial (NCT01766401 ClinicalTrials.gov). Participants (18-70 years, inclusive) who met Diagnostic Statistical Manual Mental Disorders, 4th ed., text revision, criteria GAD randomized (1:1) to placebo or flexible-dose (20-40...

To evaluate the efficacy, safety, and tolerability of vilazodone as an acute treatment for generalized anxiety disorder (GAD). Vilazodone is a selective serotonin reuptake inhibitor 5-HT1A receptor partial agonist approved major depressive in adults.This was randomized, placebo-controlled, parallel-group, multicenter, flexible-dose study conducted from May 2013-March 2014. Adult patients (18-70 years, inclusive) who met DSM-IV-TR criteria GAD were randomized (1:1) to placebo or 20-40 mg/d 8...

Purpose: Relapse and treatment adherence to paliperidone palmitate once-monthly (PP1M) three-monthly (PP3M) formulations in patients with schizophrenia were evaluated compared using health claims data.Patients Methods: Data (June 2015─June 2018) obtained from the MarketScan ® Multi-State Medicaid Database retrospectively analyzed.Patients aged ≥18 years ≥1 claim for diagnosis prior and/or at index date (i.e., of first PP3M prescription record same month/year as matched PP1M patients)...

The aim of this study is to evaluate the effects vilazodone on sexual functioning in healthy, sexually active adults and assess impact medication nonadherence type trial. Participants were randomized (20 or 40 mg/day), paroxetine placebo for 5 weeks double-blind treatment. primary endpoint was change from baseline day 35 Change Sexual Functioning Questionnaire (CSFQ) total score intent-to-treat (ITT) population. Post-hoc analyses carried out modified (mITT) populations that excluded...